Like apoptosis, oncogene-induced senescence is a barrier to tumor development. However, relatively little is known about the signaling pathways mediating the senescence response. p38-regulated/activated protein kinase (PRAK) is a p38 MAPK substrate whose physiological functions are poorly understood. Here we describe a role for PRAK in tumor suppression by demonstrating that PRAK mediates senescence upon activation by p38 in response to oncogenic ras. PRAK deficiency in mice enhances DMBAinduced skin carcinogenesis, coinciding with compromised senescence induction. In primary cells, inactivation of PRAK prevents senescence and promotes oncogenic transformation. Furthermore, we show that PRAK activates p53 by direct phosphorylation. We propose that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras-induced senescence and tumor suppression.
INTRODUCTION
p38 MAPK mediates multiple cellular processes, including proliferation, differentiation, inflammation, and stress responses (Ono and Han, 2000) . p38-regulated/activated protein kinase (PRAK, or MK5) is one member of the p38 downstream Ser/Thr protein kinase family (New et al., 1998; Shi and Gaestel, 2002) . However, PRAK À/À mice display normal LPS-induced cytokine production and endotoxic shock (Shi et al., 2003) , suggesting that PRAK may not be essential for inflammation and stress responses. The physiological role and downstream target of PRAK thus remain undefined.
Senescence is a stable proliferative arrest associated with the exhaustion of replicative potential as a result of telomere erosion during cell divisions (Shay and Wright, 2005) . Telomere length-independent senescence can be induced prematurely by activated oncogenes such as ras (Serrano et al., 1997) . As a result, cellular transformation by ras requires cooperation from ''immortalizing'' oncogenes that overcome the senescence response (Land et al., 1983) . These observations imply that, like apoptosis, premature senescence induced by ras or other oncogenes serves as an antitumorigenic defense mechanism. Several recent studies have shown that oncogene-induced senescence indeed occurs and provides an initial barrier to tumorigenesis in vivo (Collado et al., 2005; Michaloglou et al., 2005; Braig et al., 2005; Chen et al., 2005) .
Despite recent demonstrations of the in vivo significance of oncogene-induced senescence, little is known about the molecular machineries mediating the senescence response. Studies have indicated that the ability of ras to induce senescence depends on the Raf-MEK-ERK MAPK pathway (Lin et al., 1998; Zhu et al., 1998) and is accompanied by upregulation of p16 INK4A , p53, p14/p19 ARF , and/or p21 WAF1 (Serrano et al., 1997; Ferbeyre et al., 2002 ) and silencing of E2F target genes (Narita et al., 2003) . Transcriptional activation of p19 ARF by DMP1 (Sreeramaneni et al., 2005 ) also contributes to ras-induced senescence. Recently, we and others have shown that ras-induced senescence requires activation of p38 (Wang et al., 2002; Iwasa et al., 2003; Haq et al., 2002) . However, it remains unclear how activated p38 transduces the senescence signals. More importantly, the role of the p38 pathway in senescence and tumor suppression in vivo remains elusive. In this study, we uncover a novel function of PRAK in tumor suppression and ras-induced senescence. PRAK deficiency leads to increased skin carcinogenesis in mice and renders primary cells more susceptible to oncogenic transformation. The tumor-suppressing effect of PRAK is likely due to its ability to mediate ras-induced senescence, by modulating p53 activity through direct phosphorylation. Our studies define a signaling cascade that plays an essential role in ras-induced senescence and tumor suppression.
RESULTS

Targeted Deletion of PRAK Promotes Skin Carcinogenesis in Mice
We generated a line of PRAK knockout mice (see Figure S1 in the Supplemental Data available with this article online), which were viable and fertile and showed no apparent health problems. Although PRAK is activated by p38 in response to stresses (New et al., 1998) , the PRAK À/À mice responded normally to endotoxin shock and showed unaltered cytokine production in response to LPS (unpublished data) , suggesting that PRAK may not be essential for inflammatory responses.
In search of phenotypes of PRAK À/À mice, we assessed the susceptibility of PRAK +/+ , PRAK +/À , and PRAK À/À mice to skin carcinogenesis induced by a well-characterized mutagen, dimethylbenzanthracene (DMBA). DMBAinduced skin carcinogenesis is divided into three stages: initiation (induction of stable oncogenic mutations, such as ras activation, by DMBA), promotion (proliferation of genetically altered cells), and progression (conversion of papillomas to invasive carcinomas) (DiGiovanni, 1992) . In the presence of a tumor promoter such as TPA (two-stage protocol), DMBA induces efficient skin tumor formation, while without TPA (one-stage protocol), DMBA-induced tumor formation is poor in most strains. The PRAK-deficient mice were initially analyzed using the one-stage protocol, which has been successfully used to demonstrate the tumor-suppressing function of several senescence-related genes such as the INK4a locus (Serrano et al., 1996) , p19 ARF (Kamijo et al., 1999) , and DMP1 (Inoue et al., 2001) . Newborn PRAK +/+ , PRAK +/À , and PRAK À/À littermates from heterozygous crosses were treated with a single dose of DMBA and monitored for a year ( Figure 1A ). DMBA alone induced tumor formation poorly in wild-type mice. Only 1 of 12 DMBA-treated PRAK +/+ mice developed a skin papilloma.
In contrast, 8 of 13 (62%) DMBA-treated PRAK À/À mice displayed health problems, out of which 7 developed skin papillomas and 1 died of unidentified causes ( Figure 1A ). DMBA also induced papillomas in 12 of 30 (40%) PRAK +/À mice within the same period. In the untreated control groups, all 9 PRAK +/+ , 25 PRAK +/À , and 10 PRAK À/À animals remained healthy and tumor-free for at least 2 years (data not shown). Therefore, PRAK deficiency greatly enhances DMBA-induced skin carcinogenesis and allows efficient tumor induction in the absence of any tumor promoter, suggesting that PRAK loss can functionally replace a tumor promoter. Supporting this notion, PRAK deficiency had no effect on the incidence or latency of skin tumors induced by the twostage protocol ( Figure S2A ). In the presence of the tumor promoter TPA, DMBA induced skin papillomas in 6 of 7 wild-type mice and 14 of 16 PRAK-deficient (PRAK 
Senescence Induction Is Compromised in Skin
Tumors from PRAK-Deficient Mice Over 90% of DMBA-induced skin tumors contain activated Ha-ras (Quintanilla et al., 1986) . Thus, our observation that PRAK deficiency promotes DMBA-induced skin carcinogenesis raises the possibility that PRAK is essential for an in vivo tumor-suppressing mechanism against activated ras. Since oncogene-induced senescence is a barrier to tumorigenesis in vivo and p38 plays a major role in ras-induced senescence (Wang et al., 2002) , we investigated whether enhanced skin carcinogenesis resulted from a defect in senescence induction in PRAKdeficient mice. The skin tumors induced by DMBA or DMBA+TPA in all the animals were superficial papillomas consisting of an inner connective tissue vascular core, a stratified squamous epithelium with basal cells, and an outer surface of keratin ( Figure 1E and Figure S2B ; H/E). Only one of the DMBA-induced PRAK +/À papillomas progressed to a malignant carcinoma, 5 months after initial detection. While the tumors induced by DMBA in PRAK À/À and PRAK +/À mice grew slowly but progressively and usually reached a size of more than 10 mm in diameter within 2-3 months of initial detection, the DMBA-induced tumor from the wild-type mouse seemed to be dormant and remained at about 2-3 mm in diameter after 2 months (data not shown). Compared to the wild-type tumors, DMBA-induced PRAK-deficient papillomas also had more complicated structures, with much thicker and more folded layers of squamous epithelium ( Figure 1E ). We analyzed senescence and proliferative markers in tumors removed from animals treated with DMBA alone. The PRAK +/+ papilloma contained large areas of cells positive for the senescence-associated b-galactosidase (SA-b-gal) marker in squamous epithelium, whereas SAb-gal was undetectable in PRAK +/À and PRAK À/À tumors ( Figure 1E and Figures S3A and S3B ). The absence of SA-b-gal in PRAK-deficient tumors was not a result of a general defect in this enzyme due to PRAK deletion, as it was readily detectable in normal skin from adult mice of all three genotypes, including skin adjacent to the PRAK-deficient papillomas ( Figure S3C ). Other senescence markers, including those identified in a recent study (Collado et al., 2005) , were further examined. In western blot analysis, expression of p16 INK4A , DcR2, and Dec1 was increased in the PRAK +/+ papilloma in comparison to in adjacent normal skin, while these increases were abolished in PRAK +/À ( Figure S4 ) and PRAK À/À (data not shown) tumors. The absence of induction of the senescence markers was confirmed in both PRAK +/À and PRAK À/À tumors by immunohistochemistry ( Figure 1E ).
The majority of the cells in the squamous epithelium of the PRAK +/+ tumor, including undifferentiated and differentiated basal cells, were negative for the proliferation marker Ki-67 but positive for p16 INK4A and DcR2, ing that these cells were growth arrested and senescent. In contrast, most cells in the basal layers of PRAK +/À and PRAK À/À papillomas were positive for Ki-67 but negative for DcR2 and p16 INK4A , and only the denucleated, highly differentiated cells immediately adjacent to keratin contained high DcR2 and p16 levels. Therefore, senescence induction is compromised in PRAK-deficient tumors. Taken together, our results suggest that DMBA-induced skin carcinogenesis is initially restricted by senescence in wild-type mice, which prevents papilloma formation and/or keeps the tumors in dormancy upon their formation. PRAK deletion compromises senescence induction, leading to increased incidence and more efficient formation of DMBA-induced tumors. The senescence markers were also analyzed in the DMBA+TPA-induced tumors. While the DMBA+TPA-induced PRAK-deficient tumors had no detectable SA-bgal and were essentially negative for DcR2 and p16
INK4A
in the underdifferentiated layers of the squamous epithelium, the wild-type tumors contained patches of cells weakly positive for DcR2 and p16
INK4A and a few small SA-b-gal-positive areas ( Figure S2B ). However, both wild-type and PRAK-deficient tumors contained substantial amounts of Ki-67-positive cells in the squamous epithelium ( Figure S2B ) and seemed to grow slowly but steadily. Thus, at least a substantial portion of the wildtype tumor is proliferative and might have bypassed senescence in the presence of the tumor promoter TPA. It is unclear how TPA allows proliferation of cells containing activated ras in wild-type tumors and whether TPA truly disrupts senescence in these cells. TPA did not prevent ras-induced senescence in primary fibroblasts (data not shown). Nevertheless, the reduced levels of the senescence markers in the DMBA+TPA-induced wild-type tumors as compared to the DMBA-induced wild-type tumors ( Figure 1E and Figure S2B ) are consistent with a role of PRAK-mediated senescence in suppressing the tumor promotion stage during skin carcinogenesis.
PRAK Is Essential for ras-Induced Senescence in Primary Murine and Human Fibroblasts
To further establish the essential role of PRAK in rasinduced senescence responses, we examined the role of PRAK in ras-induced senescence in primary cells. PRAK +/+ primary mouse skin fibroblasts (MSFs) became growth arrested ( Figure 2A ) and accumulated SA-b-gal ( Figure 2C ) upon transduction of an activated ras allele, Ha-RasV12 ( Figure 2B ), indicating that ras triggered premature senescence. By contrast, Ha-RasV12-induced proliferative arrest or the SA-b-gal marker was abolished in PRAK À/À cells and partially blocked in PRAK +/À cells (Figures 2A and 2C) . Therefore, the deletion of PRAK compromised the senescence response in primary MSFs. Similarly, PRAK deletion abolished ras-induced senescence in primary mouse embryonic fibroblasts (MEFs) ( Figure 2D and Figure S5A ). Supporting the disruption of ras-induced senescence in PRAK-deficient cells, the induction of the senescence markers DcR2, Dec1, p16
INK4A
, and p19 ARF by ras was either modestly or greatly reduced in PRAK +/À and PRAK À/À MEFs when compared to wildtype cells ( Figure S5C ). The disruption of ras-induced senescence was a specific result of the loss of PRAK because wild-type PRAK, but not its kinase-dead mutant (KM) (Lys51 to Met), restored the senescence response when reintroduced into the PRAK À/À MEFs ( Figure 2D ).
These findings demonstrate that PRAK is essential for the ras-induced senescence response in primary mouse fibroblasts.
The requirement of PRAK in ras-induced senescence was further investigated in primary human fibroblasts. Two PRAK shRNAs, shPK-1 and -2, reduced PRAK expression ( Figure 3A ) and ras-induced PRAK kinase activity when stably transduced into BJ human fibroblasts ( Figure 3B ). These two PRAK shRNAs prevented HaRasV12-induced proliferative arrest ( Figure 3C ) and accumulation of SA-b-gal ( Figure 3D and Figure S5A ). The same results were obtained in BJ cells at a much earlier passage (PD15, passage 6) or when a scrambled shPK-1 sequence was used as control ( Figure S6 ). Thus, PRAK is essential for ras to induce premature senescence in primary human fibroblasts. The induction of a recently identified senescence marker, p15 INK4B , by ras was also abolished in BJ cells with PRAK knockdown ( Figure S5D ).
To rule out a possible off-target effect of PRAK shRNAs on senescence, murine PRAK (mPRAK) that could not be silenced by shPK-1 and shPK-2 ( Figure 3E ) was transduced into BJ cells to rescue PRAK expression. mPRAK restored ras-induced senescence in BJ cells expressing PRAK shRNA, but not in cells with p53 knockdown (Figures 3C and 3D) . These results indicate that the bypass of ras-induced senescence in BJ cells is due to specific silencing of PRAK. In contrast to p53 shRNA, PRAK shRNA did not prevent G1 arrest induced by g-irradiation or UV light ( Figure S7A ), suggesting that PRAK is selectively required for ras-induced senescence, but not for DNA-damage-induced responses.
PRAK Deficiency Promotes Cellular Transformation
We further tested whether disrupting the senescence response by PRAK deficiency would permit transformation by ras alone in the absence of immortalizing oncogenes. Similar to p53 À/À primary MSFs, primary PRAK À/À MSFs and MEFs were not tumorigenic by themselves but were readily transformed into tumorigenic cells by Ha-RasV12 alone, which formed robust colonies without anchorage and produced subcutaneous tumors with high frequency when injected into nude mice ( Figure 4A ). PRAK +/À cells were also transformed, although less efficiently, by HaRasV12 (data not shown). These results demonstrate that eliminating PRAK renders primary murine fibroblasts susceptible to oncogenic transformation by ras. BJ primary human fibroblasts can be fully transformed by a combination of E1A, MDM2, and Ha-RasV12 (Seger et al., 2002) (Figure 4B ). We tested whether PRAK knockdown could replace any of the oncogenes in this cellular transformation model. PRAK shRNA alone or in combination with Ha-RasV12 or Ha-RasV12 and MDM2 did not cause transformation. Interestingly, BJ cells transduced with E1A, PRAK shRNA, and Ha-RasV12 formed soft-agar colonies and generated subcutaneous tumors as efficiently as the BJ/E1A/MDM2/Ha-RasV12 cells (Figures 4B and 4C) . As noticed by others (Seger et al., 2002) , BJ cells expressing E1A and Ha-RasV12 formed a modest amount of small colonies on soft agar, but they were not fully transformed because they did not develop tumors in nude mice ( Figures 4B and 4C) . Therefore, PRAK knockdown functionally replaced MDM2 and cooperated with E1A and Ha-RasV12 to transform normal human fibroblasts.
PRAK Kinase Activity Is Induced in Senescent Cells in a p38-Dependent Manner
We determined whether the PRAK kinase activity was induced in senescent cells using HSP27 as a substrate. PRAK protein was immunoprecipitated from either wildtype BJ cells or BJ cells undergoing premature senescence induced by either Ha-RasV12 or constitutively active MKK3 or MKK6. PRAK from senescent cells displayed an increased kinase activity in comparison to that from wild-type BJ cells ( Figure 5A ). ras-induced PRAK activation was also detected in primary MEFs ( Figure 5B ). ras-and MKK3/6E-induced PRAK kinase activity was greatly reduced in both BJ and MEF cells by a specific p38 inhibitor, SB203580 (Figures 5A and 5B) . This, combined with our previous finding that p38 is activated during senescence (Wang et al., 2002) , indicates that PRAK is activated by p38 during ras-induced senescence. Furthermore, PRAK and p38 immunoprecipitated from the DMBA-induced papilloma in the wild-type mouse also showed increased kinase activity toward their substrates, HSP27 and ATF2 respectively, in comparison to the proteins isolated from normal skin in the same mouse ( Figure 5C ). Since this tumor displayed senescence features ( Figure 1E and Figure S4 ), our results confirm that PRAK and p38 are activated in senescent cells in vivo, and they are consistent with the essential role of these kinases in establishing the senescence response in DMBA-induced tumors. 
PRAK Overexpression Enhances ras-Induced
Senescence Since ectopically expressed HA-PRAK is activated in BJ cells by Ha-RasV12 and MKK3E in a manner similar to endogenous PRAK ( Figure S8 ), overexpression of PRAK should enhance PRAK-mediated signaling. Therefore, we investigated the consequences of PRAK overexpression on senescence. Overexpression of wild-type PRAK caused a slight reduction in cell proliferation rate without a detectable increase in the SA-b-gal marker ( Figures 5D  and 5E ). Thus, PRAK alone was not sufficient to induce premature senescence, possibly due to the lack of upstream signals that activate PRAK. Indeed, Ha-RasV12 induced more robust senescence phenotypes in conjunction with overexpressed PRAK than by itself. When compared with Ha-RasV12 alone, coexpression of HaRasV12 with PRAK resulted in stronger growth inhibition ( Figure 5D ) and twice as many SA-b-gal-positive cells on day 7 after ras transduction ( Figure 5E ). PRAK also enhanced cell enlargement, another characteristic of senescence ( Figure S9A ). By contrast, no difference was observed in the percentage of apoptotic cells between these two populations ( Figure S9B ), indicating that the stronger growth inhibition in PRAK/Ha-RasV12 cells resulted from enhanced senescence but not increased apoptosis. The effect of PRAK on senescence requires its activation and its kinase activity since the activationsite mutant (T182A) and the kinase-dead mutant (KM) of PRAK (New et al., 1998) failed to enhance ras-induced senescence ( Figures 5D and 5E and Figure S9A ), even though their levels of expression were comparable to wild-type PRAK ( Figure 5F ). These results demonstrate that PRAK is a rate-limiting factor during senescence in BJ cells and that an increase in PRAK expression levels sensitizes cells to ras-induced senescence.
PRAK Is Essential for Senescence-Induced p53
Transcriptional Activity ras-induced senescence is mediated by sequential activation of the ERK and p38 pathways (Wang et al., 2002) ; hypophosphorylation of pRb; and silencing of E2F targets such as PCNA, MCM3, and cyclin A (Serrano et al., 1997; Narita et al., 2003) . In an attempt to determine the signaling step on which PRAK acts, we found that PRAK knockdown in BJ cells did not alter activation of ERK or p38 by ras ( Figure 6A ) but prevented the silencing of the E2F targets PCNA, MCM3, and cyclin A ( Figure 6B ). This indicates that PRAK functions between p38 and E2F during senescence. The ability of PRAK shRNA to replace MDM2, a negative p53 regulator, in transforming BJ cells ( Figure 4B ) raises the possibility that PRAK may mediate ras-induced senescence by targeting p53. Thus, we examined whether PRAK was required for oncogenic ras-induced p53 transcriptional activity using a retrovirus-based, stable luciferase reporter system for p53 (Deng et al., 2005) . In both BJ and wild-type MEF cells containing this p53 reporter, luciferase activity was stimulated significantly by Ha-RasV12 or MKK3E (Figure 6C ), confirming the induction of p53 transcriptional activity in senescence. ras-and MKK3-induced p53 activity was greatly reduced in PRAK-deficient BJ and MEF cells. Neither Ras/MKK3E nor the PRAK shRNA significantly altered the transcription of MG-Luc, a control reporter containing mutant p53 binding sites (Deng et al., 2005 ) (data not shown), indicating that the effects we observed were specific for p53. The regulation of p53 activity by PRAK during senescence was confirmed by the observation that ras-induced expression of p21 WAF1 , an endogenous p53 target previously implicated in rasinduced senescence, was abolished in PRAK-deficient BJ and MEF cells ( Figure 6D ). By contrast, PRAK shRNA did not block the induction of p53 activity or p21 WAF1 expression by UV ( Figures S7B and S7C ), in concordance with the observation that PRAK was not required for DNA-damage-induced G1 arrest ( Figure S6A ).
Together, these results suggest that PRAK mediates ras-induced senescence by stimulating p53 activity, which in turn increases p21 WAF1 expression. Supporting the importance of the PRAK-p53-p21 cascade in senescence in vivo, p21 levels were increased in the DMBA-induced papilloma when compared to the adjacent normal skin in wild-type mice, but not in the PRAK-deficient tumors in which senescence response had been compromised ( Figure S4 ).
PRAK Phosphorylates p53 at Ser37
The control of p53 activity by PRAK seems to be independent of the induction of p53 protein levels. In BJ cells, PRAK-dependent stimulation of p53 activity by ras occurred without any detectable increase in p53 protein, while in PRAK-deficient MEFs, ras failed to enhance p53 activity despite unaltered induction of the p53 protein ( Figure 6D ). Thus, PRAK may regulate p53 activity via posttranslational modifications. We explored whether PRAK directly phosphorylates p53. HA-tagged PRAK immunoprecipitated from BJ cells transduced with Ha-RasV12, MKK3E, or MKK6E readily phosphorylated human p53 in vitro ( Figure 7A ). Deletion analysis of p53 revealed that activated PRAK phosphorylates human p53 within the N-terminal TAD (residues 1-61) ( Figure 7B ). Unlike wild-type PRAK, the kinase-dead mutant (KM) and the activation-site mutant (T182A) isolated from ras-or MKK3-expressing cells failed to phosphorylate p53 ( Figure 7B ).
Recombinant PRAK phosphorylated p53(1-61) in vitro ( Figure 7C , insert), indicating that p53 is a direct substrate of PRAK. To identify the PRAK phosphorylation site in p53, p53(1-61) phosphorylated by PRAK was subjected to phosphopeptide mapping by mass spectrometry (Figure 7C) . Spectrum searches revealed a significant number of phosphopeptides that contained phospho-Ser37, but none containing the other phosphoresidues, indicating that Ser37 is the only site of phosphorylation by PRAK. Confirming this notion, mutation of Ser37 to Asp essentially abolished phosphorylation by recombinant PRAK or PRAK immunoprecipitated from senescent cells, while mutations of Ser15 or Ser33 had no effect on p53 phosphorylation ( Figures 7D and 7E ). The S37D protein was accessible to kinases since it was readily phosphorylated by recombinant and immunoprecipitated p38 at Ser33 (Figure S10 ), as previously reported (Bulavin et al., 1999) .
Ser37 of p53 is a conserved residue in mammals (Figure 7F) . The N-terminal TAD of murine p53 (residues 1-57) was readily phosphorylated by PRAK. The S37D mutation, but not the mutation of Ser18 (equivalent to Ser15 in hp53), disrupted phosphorylation of mp53 by PRAK ( Figure 7F ), indicating that Ser37 of mp53 is also the phosphorylation site of PRAK.
In primary BJ cells, Ha-RasV12 or MKK3E increased phosphorylation of p53 at Ser37, and PRAK knockdown abrogated ras-and MKK3E-induced S37 phosphorylation ( Figure 7G) , while the protein level of p53 was not significantly altered. The same results were obtained with two independent PRAK shRNA constructs (data not shown). These results demonstrate that, in vivo, PRAK mediates Ser37 phosphorylation during ras-induced senescence.
We examined mp53 phosphorylation in MEFs transduced with a FLAG-tagged mp53 after metabolically labeling the cells with 32 P-orthophosphate and immunoprecipitating mp53 ( Figure 7H ). To avoid the growth inhibition resulting from stable p53 expression, an mp53 cDNA containing an A135V mutation was used. In wild-type MEFs, Ha-RasV12-induced mp53 phosphorylation was significantly reduced when Ser37 was mutated to Ala, indicating that Ser37 was one of the ras-induced phosphorylation sites. In PRAK À/À MEFs, ras-induced mp53 phosphorylation was lower than in the wild-type cells. More importantly, the S37A mutation did not further reduce mp53 phosphorylation, suggesting that PRAK is responsible for ras-induced phosphorylation of Ser37 in MEFs. Furthermore, PRAK immunoprecipitated from the wild-type papilloma had an increased kinase activity toward Ser37 of mp53 when compared to PRAK from the adjacent normal skin ( Figure 7I ). This indicates that Ser37 is likely phosphorylated by activated PRAK in tumors that display senescence features.
To analyze the contribution of Ser37 to ras-induced senescence, the effect of ectopic expression of the p53S37A mutant was examined. To avoid growth inhibition by high p53 expression levels from the conventional pBabePuro vector, we used a binary retroviral vector (Deng et al., 2004) to express p53 at levels that were only 2-to 3-fold higher than the endogenous protein ( Figure S11A ) and did not cause significant growth inhibition in BJ cells (Figure S11B) . Ha-RasV12 caused a stronger growth arrest ( Figure S11B ) in BJ cells expressing wild-type p53 than in control BJ cells, indicating an enhancement of rasinduced senescence by p53. p53 did not affect the rate of apoptosis in the presence or absence of ras (Figure S12) . The ability of p53 to enhance ras-induced senescence was abolished by the S37A mutation ( Figure S11B ), supporting a key role of PRAK-mediated p53 phosphorylation in senescence. Mutation of Ser15 and Ser33, the other two sites shown to be phosphorylated during rasinduced senescence (Ferbeyre et al., 2002; Bulavin et al., 2002) , also disrupted the enhancement of senescence. Therefore, p53-mediated senescence may rely on phosphorylation of multiple sites.
DISCUSSION
Although the requirement of p38 in ras-induced senescence suggests a potential tumor-suppressing function of this pathway, a direct assessment of the consequences of p38 inactivation on tumorigenesis in vivo has been difficult, due partly to the embryonic lethality of p38 knockout in animals. Supporting an anti-oncogenic role of p38, deletion of a multifunctional p38 phosphatase, Wip1, suppresses mammary tumor development in mice (Bulavin et al., 2004) . Our finding of enhanced skin carcinogenesis upon PRAK deletion demonstrates that the p38 pathway functions through PRAK to suppress tumorigenesis. Moreover, we show that increased tumor induction by DMBA is accompanied by compromised senescence induction in PRAK-deficient mice, suggesting that PRAK-mediated senescence is a barrier to skin carcinogenesis in vivo.
Our data suggest that PRAK-mediated senescence likely suppresses skin carcinogenesis at the tumor promotion stage. Since tumor promotion, by definition, involves proliferation of genetically altered cells such as those containing activating ras mutations, it is conceivable that ras-induced senescence is a major barrier in this step, which needs to be disrupted for efficient tumor induction. In the mouse strain (129 3 C57BL/6) used in our study, PRAK did not significantly increase the rate of papillomato-carcinoma conversion. However, since the papillomato-carcinoma conversion rate is extremely low in this background, we cannot exclude the possibility that PRAK deletion enhances progression in other strains with higher conversion rates.
In contrast to p53-and p19 ARF -deficient mice (Jacks et al., 1994; Donehower et al., 1992; Kamijo et al., 1999) , PRAK-deficient mice did not develop spontaneous tumors within 2 years after birth. This difference indicates that, although p53 activity is regulated by p38-PRAK in ras-induced senescence, p53 and p19 ARF likely have additional tumor-suppressing activities that are not regulated by PRAK. Like many other pathways that mediate the tumor-suppressing activity of p53, the p38-PRAKp53 circuitry may only be essential for tumor suppression under specific cancer-causing conditions, such as when oncogenic ras mutations are induced. Our data demonstrate that this pathway is indispensable in tumor suppression during ras-driven tumorigenesis. Previous studies on the regulation of p53 in senescence have focused mainly on the induction of p53 protein levels. However, p53 protein levels are unaltered during rasinduced senescence in some primary cells , including the BJ cells used in this study, suggesting that the regulation of p53 occurs at posttranslational levels. Several p53 residues, including Ser15, Ser33, and Ser46, were shown to be phosphorylated in senescent cells (Ferbeyre et al., 2002; Bulavin et al., 2002) . While the kinase for Ser15 in senescent cells is unknown, Ser33 and Ser46 are phosphorylated directly by p38 upon ras activation. Nevertheless, it remains unclear whether phosphorylation of each site is functionally relevant in senescence. Using a retrovirus-based stable p53 reporter and a binary retroviral vector directing a low level of p53 expression that is not growth inhibitory, we demonstrate that PRAK is essential for p53 activation during premature senescence and that phosphorylation of Ser37, Ser15, and Ser33 is critical for p53 to mediate senescence. Thus, full activation of p53 in the senescence pathway may require phosphorylation of multiple sites.
DNA-PK and ATR have been reported to phosphorylate p53-Ser37 in response to DNA damage (Lees-Miller et al., 1992; Tibbetts et al., 1999) . While we cannot rule out the possible contribution of DNA-PK and ATR to Ser37 phosphorylation in the senescence pathway, PRAK seems to be the major Ser37 kinase during senescence because ras-induced Ser37 phosphorylation is essentially abolished in PRAK-deficient human and mouse cells ( Figures  7G and 7H ). On the other hand, UV-induced Ser37 phosphorylation in BJ cells ( Figure 7G ) is unlikely to be mediated by PRAK since PRAK is not required for DNA-damageinduced p53 activity and cell-cycle arrest ( Figure S7 ). Therefore, it is likely that p53-Ser37 phosphorylation is mediated primarily by different kinases in the DNAdamage pathway and the senescence pathway.
EXPERIMENTAL PROCEDURES
Cell Culture BJ and LinX-A cells were maintained as described (Wang et al., 2002) . Primary mouse skin fibroblasts were isolated from 12-to 15-day-old mice. The skin on the back was excised, washed with PBS, incubated with 0.05% trypsin-EDTA at 37 C for 15 min, minced, and digested in 4 ml of 2 mg/ml collagenase A (Roche) at 37 C for 2-3 hr. The digestion was stopped by the addition of 10 ml of medium. Cells were collected and seeded in the medium used for LinX-A. MEFs were isolated from day 14 embryos using a published protocol (Serrano et al., 1997) .
Plasmids E1A and Ha-RasV12 vectors were obtained from Dr. Scott Lowe (Cold Spring Harbor Laboratory). Retroviral vectors for HA-hPRAK or mPRAK were constructed by cloning PRAK cDNA (New et al., 1998; New et al., 2003) into BabePuro or WZLHygro. Oligonucleotides for shRNA targeting PRAK (shPK-1, 5 0 -GCTGGAATTAGTGGTCCAG-3 0 ;
shPK-2, 5 0 -GTGTCTATATCCACGACCA-3 0 ), p53, and GFP (Brummelkamp et al., 2002b) were cloned into pSUPER.retro according to a published protocol (Brummelkamp et al., 2002a) . Retroviral vectors for MKK3/6E (Wang et al., 2002) and MDM2 (Sun et al., 1998) and retroviral p53 reporter PG-Luc and its non-p53-binding control MGLuc (Deng et al., 2005) have been reported previously. To create p53 expression vectors, p53 cDNA was cloned into pcDNA3, BabePuro, or a binary vector (GAPDH-PGK-Puro) (Deng et al., 2004) . p53 mutants were generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Retrovirus-Based Gene Transduction
Retrovirus-based gene transduction was carried out as previously described (Sun et al., 1998) . Transduced cells were purified with 120 (BJ) or 75 (MEF and MSF) mg/ml hygromycin B, 400 mg/ml G418, 5 mg/ml blasticidin, and/or 1.2 mg/ml puromycin.
Western Blot Analysis
Western blot analysis was performed with lysates prepared 6-8 days after transduction of Ras or MKK3/6E from subconfluent cells as described (Wang et al., 2002 
Analysis of Senescence
Analysis of senescence in cell culture was performed as described previously (Wang et al., 2002) . To quantify SA-b-gal positives, at least 200 cells were counted in random fields in each of the duplicated wells.
To detect SA-b-gal in vivo, 10 mm frozen sections of papilloma or normal skin were fixed in 0.2% glutaraldehyde/PBS for 10 min at 4 C, washed with PBS (pH 6.0), stained with 1 g/l X-gal/1 mM K 4 Fe(CN) 6 /5 mM K 3 Fe(CN) 6 /2 mM MgCl 2 in PBS (pH 6.0) for overnight at 37 C, washed with H 2 O, counterstained with eosin, and dehydrated in an ethanol gradient with toluene. For immunohistochemistry of senescence markers, 8 mm frozen sections of tumors were fixed in 4% PFA; permeabilized in 0.1% Triton X-100/PBS; blocked in 4% BSA/ 0.1% Triton X-100/PBS for 1 hr at room temperature; and incubated with primary antibodies (Ki-67, Lab Vision, 1:100; DcR2, Stressgen, 1:500; p16 M156, Santa Cruz, 1:500; PRAK, 1:750) in 4% BSA/0.1% Triton X-100/PBS overnight at 4 C, with biotinylated goat anti-rabbit IgG for 2 hr at room temperature, and finally with ABC-HRP (Vector Laboratories) for 2 hr at room temperature. The slides were developed with DAB/H 2 O 2 , counterstained with hematoxylin, and dehydrated with an ethanol gradient and toluene.
Tumorigenesis Assays BJ and murine fibroblasts were transduced with indicated oncogenes at PD18.9 and passage 2, respectively. For anchorage-independent growth, 3-4 3 10 4 BJ cells at PD25 or mouse fibroblasts at passage 3 were resuspended in a medium containing 0.3% low-melting-point agarose and plated onto a solidified bottom layer medium containing 0.5% agarose in 6 cm plates. Colonies were photographed after 2-4 weeks, stained with 0.02% Giemsa, and counted. For tumor formation assays, 2 3 10 6 BJ cells at PD28 or 10 6 mouse fibroblasts at passage 4 were injected subcutaneously into the flanks of 6-week-old female HSD:athymic nude mice in 100 ml of serum-free RPMI1640. Tumor growth was monitored weekly for 10 weeks. p53 Reporter Assays BJ cells at PD25 were transduced with PG-Luc or MG-Luc (Deng et al., 2005) ; shPRAK, shp53, or shGFP; and Ha-RasV12, MKK3E, MKK6E, or vector; split into 12-well plates on day 7 post ras transduction; and lysed on day 8. MEFs were transduced at passage 2 with PG-Luc or MG-Luc and Ha-RasV12 or vector, split on day 6, and lysed on day 7. Luciferase activity was determined and normalized to protein concentrations.
Immunoprecipitation/Western Blot Analysis
Immunoprecipitation/western blot analysis was performed as described (Deng et al., 2005) , except that p53 was immunoprecipitated from 1 mg of each lysate from subconfluent BJ cells (PD28-30) using agarose-conjugated anti-p53 DO-1 and Pab1801 (5 mg each).
Recombinant Proteins pGEX-hp53(FL) was a gift from Dr. Roberta Maestro (CRO, Aviano, Italy). Recombinant HSP27, GST-ATF2, GST-full-length p53, His-PRAK, and His-p38 were prepared as described previously (New et al., 1998; New et al., 2003) . hp53(1-61) and mp53(1-54) were coexpressed with the ZZTAZ2 domain of CBP from a bicistronic vector to enhance protein stability and were purified as described (Legge et al., 2004) .
PRAK Kinase Assays BJ cells were lysed at PD30-40 on day 6-8 post ras/MKK3/6E transduction in buffer containing 50 mM HEPES (pH 7.5), 2.5 mM EGTA, 1 mM EDTA, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 50 mM NaF, 1 mM sodium vanadate, 1 mM b-glycerophosphate, 1 mM DTT, and Complete protease inhibitors. Cells were treated with 8 mM of SB203580 for 6-8 days before lysis if necessary. Papillomas and skin tissues were minced, homogenized, and sonicated in the same buffer. One hundred to three hundred micrograms of lysate was incubated with 60 ml anti-HA antibody 12CA5 or 6 ml anti-PRAK or anti-p38 antibody (New et al., 1998 ) at 4 C for 2 hr, followed by incubation with 30 ml of protein G or 40 ml of protein A Sepharose at 4 C for 2 hr. The beads were washed three times with 1 ml of lysis buffer and three times with 13 kinase buffer (50 mM HEPES [pH 7.5], 0.5 mM EGTA, 10 mM MgCl 2 , 0.1 mM PMSF, 1 mM NaF, 0.1 mM sodium vanadate, 0.1 mM b-glycerophosphate, and 1 mM DTT). The reactions were performed in 20 ml of 13 kinase buffer (above) with 10 mM ATP, 0.5 ml of [g-32 P]ATP and 5-10 mg of HSP27, 7-10 mg of GST-p53, hp53(1-61) or mp53(1-57), or 2 mg of GST-ATF2 at 30 C for 45 min. Assays with recombinant kinases were performed at 30 C for 2 hr in 20 ml of 13 kinase buffer without EGTA, containing 10-12 mg of hp53(1-61) or mp53(1-57), 2 mg of His-PRAK or His-p38, and 0.5 ml of [g-32 P]ATP. The reactions were stopped by 7 ml of 43 Laemmli buffer, heated at 95 C, and separated by SDS-PAGE. Radioactive signals were detected by a phosphorimager.
In Vivo Phosphorylation of mp53 PRAK +/+ or PRAK À/À MEFs transduced with FLAG-mp53A135V, FLAG-mp53A135V/S37A, or vector were labeled at passage 4 on day 6 posttransduction of Ha-RasV12 or vector with 2 mCi of [ 32 P]phosphorus in 8 ml of medium (with dialyzed FCS) for 5 hr. Cells were lysed in 200 ml of NETN (Deng et al., 2005) . FLAG-mp53 was immunoprecipitated from 72 mg of each lysate with 36 ml of agaroseconjugated anti-FLAG M2 antibody (Sigma), separated by SDS-PAGE, and transferred to a nitrocellulose membrane. Radioactive signals were detected by a phosphorimager. Total mp53 protein levels were detected by western blot.
Phosphopeptide Mapping A published method was followed with minor modifications (MacCoss et al., 2002) . Sixty-three micrograms of hp53(1-61) protein phosphorylated by PRAK or left unphosphorylated was denatured by 8M urea/ 100 mM Tris (pH 8.5); reduced; alkylated; and digested with Glu-C, Asp-N, or elastase. Formic acid was added to combined reactions to a final concentration of 5%. MS analysis was performed using a nine-step multidimensional separation described previously (Washburn et al., 2001) . The spectra were searched with SEQUEST (Eng et al., 1994 ) against a combined human/mouse/rat protein database with or without the addition of 80 on S, T, or Y (phosphorylation) or with a loss of 18 on S or T (neutral loss of phosphoric acid from phospho-S or -T).
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